Longeveron Inc. (NASDAQ:LGVN) Short Interest Update

Longeveron Inc. (NASDAQ:LGVN) was the target of a large increase in short interest in February. As of February 27th, there was short interest totaling 1,530,744 shares, an increase of 22.9% from the February 12th total of 1,245,318 shares. Based on an average daily trading volume, of 597,234 shares, the short-interest ratio is currently 2.6 days. Approximately 8.1% of the company’s stock are sold short. Approximately 8.1% of the company’s stock are sold short. Based on an average daily trading volume, of 597,234 shares, the short-interest ratio is currently 2.6 days.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Longeveron in a research note on Thursday, January 22nd. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $6.50.

Hedge Funds Weigh In On Longeveron

An institutional investor recently bought a new position in Longeveron stock. XTX Topco Ltd purchased a new stake in Longeveron Inc. (NASDAQ:LGVN) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 48,003 shares of the company’s stock, valued at approximately $62,000. XTX Topco Ltd owned about 0.32% of Longeveron at the end of the most recent reporting period. 10.01% of the stock is currently owned by hedge funds and other institutional investors.

Longeveron Stock Up 19.9%

NASDAQ:LGVN opened at $0.97 on Monday. The company has a market capitalization of $20.69 million, a PE ratio of -0.92 and a beta of 0.23. Longeveron has a 52-week low of $0.48 and a 52-week high of $1.92. The stock’s 50 day moving average price is $0.58 and its 200 day moving average price is $0.67.

Longeveron Company Profile

Longeveron Inc is a clinical-stage biotechnology company focused on the development and commercialization of allogeneic cellular therapies designed to address aging-related and inflammatory conditions. The company’s primary therapeutic candidate, Lomecel-B, is an off-the-shelf mesenchymal stem cell product derived from bone marrow. Through its proprietary manufacturing process, Longeveron aims to produce a consistent, scalable cell therapy platform with potential applications in multiple disease areas.

Longeveron’s pipeline encompasses several ongoing and completed clinical studies.